Cystic fibrosis (CF) is the most frequent life-limiting autosomal recessive disease in
Caucasians, affecting the respiratory tract, but also the pancreas, gut, and hepatobiliary tract …

Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and
effective in people with cystic fibrosis (CF) aged⩾ 6 years with at least one F508del-CFTR …

Objective We evaluated whether implementation of cystic fibrosis (CF) newborn screening
(NBS) leads to equitable timeliness of initial evaluation. We compared age at first event …

Background The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose
tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We …

Background Airway inflammation starts in early life in cystic fibrosis (CF) and limited,
objective markers are available to help identify infants with increased inflammation. We …

Background Limited understanding of the diversity of variants in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene across ancestries hampers efforts to …

Background Universal newborn screening changed the way medical providers think about
the presentation of cystic fibrosis (CF). Before implementation of universal screening, it was …

Background and purpose Olfactory dysfunction (OD) commonly occurs in patients with
sinonasal dysfunction, but the prevalence and severity of olfactory issues in adolescents …

Background: Life expectancy has increased in cystic fibrosis (CF) patients; however, the rate
of mortality is still high, and in a majority of cases, the cause of death is due to respiratory …

Background Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in
people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later …